• Daily Marijuana Observer Facebook
  • Daily Marijuana Observer Twitter
  • Daily Marijuana Observer StockTwits
  • Daily Marijuana Observer SA
  • Daily Marijuana Observer Instagram
  • Daily Marijuana Observer Youtube
  • Pinterest Social Icon
  • Daily Marijuana Observer Talk Market

Jefferies Thinks Zynerba Will Double

According to a release from StreetInsider, investment bank Jefferies & Co. has reinstated coverage on Zynerba Pharmaceuticals Inc. (NASDAQ:ZYNE). They have assigned ZYNE a 'Buy' rating with a price target of $32.00 per share. At such a price target, this means that Jefferies sees over 120% upside potential from today's close price. It seems that analyst worries about ZYNE were calmed following the presentation of positive results at the 70th annual meeting of the American Epilepsy Society (AES).

 

CBD Gel Shows Promise

 

Jefferies analyst Biren Amin said, "At AES, ZYNE presented safety data from PI studies for ZYN002 CBD gel in healthy volunteers and patients with epilepsy. ZYN002 was well tolerated at all doses and concentrations and comparable to placebo, including the dose intended to be investigated in the PII STAR-1 trial. Notably, ZYNE reported no somnolence or fatigue, or neuropsychological effects. We are no longer restricted on ZYNE and therefore we reinstate our Buy rating and $32 PT." 

 

Market Reaction

Shares of ZYNE closed out the day up 9.71% or $1.28 per share to close at $14.46 per share. In after-hours trading shares have continued to climb, now up to another 1.66% $14.70 per share.

 

Conclusion

 

For more information and recent coverage on ZYNE, be sure to check out Zynerba's stock profile in our marijuana stocks database. Also, be sure to connect with us on social media using the links to the right of this article. 

Read more articles tagged:

Please reload

LATEST NEWS
Please reload

Please reload

DMO

© Copyright 2016-2020 Smoke Show Ventures, Inc.

RSS Feed

Disclaimer: Except for the historical information and data presented herein, matters discussed in articles on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future performance or achievements expressed or implied by such coverage. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Smoke Show Ventures, Inc., which owns The Daily Marijuana Observer, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. Smoke Show Ventures, Inc. or its affiliates, which owns The Daily Marijuana Observer, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.dailymarijuanaobserver.com/legal-disclaimer/.